SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0000950170-22-003911
Filing Date
2022-03-16
Accepted
2022-03-16 16:03:01
Documents
13
Period of Report
2022-03-16
Items
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K cyt-20220316.htm   iXBRL 8-K 51304
2 EX-99.1 cyt-ex99_1.htm EX-99.1 224114
  Complete submission text file 0000950170-22-003911.txt   410635

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT cyt-20220316.xsd EX-101.SCH 2469
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT cyt-20220316_pre.xml EX-101.PRE 11454
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT cyt-20220316_lab.xml EX-101.LAB 13987
7 EXTRACTED XBRL INSTANCE DOCUMENT cyt-20220316_htm.xml XML 4895
Mailing Address 128 SPRING STREET BUILDING A, SUITE 510 LEXINGTON MA 02421
Business Address 128 SPRING STREET BUILDING A, SUITE 510 LEXINGTON MA 02421 857-285-4140
Cyteir Therapeutics, Inc. (Filer) CIK: 0001662244 (see all company filings)

IRS No.: 455429901 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-40499 | Film No.: 22744853
SIC: 2834 Pharmaceutical Preparations